Close Menu

Imexpharm listed in Top 5 companies with best working environment in VN

The recognition demonstrated Imexpharm's great efforts in creating a happy and sustainable working environment for nearly half a century, the company said in a statement.

Representatives from Imexpharm pose for a photo after receiving the award. — VNS Photo

"The Best Places to Work in Việt Nam" award is a prestigious one granted annually by Anphabe - a consultant on Employer Branding and Happy Workplace Environment. The award is implemented through surveys and objective evaluations by employees.

This year, the survey attracted more than 63,000 employees to participate in voting and evaluation based on 45 criteria, including salary and benefits, personal development opportunities, healthcare and well-being, and good quality of life for employees.

Imexpharm ranked 54th among the top 100 companies with the best working environment in Việt Nam, rising five positions compared to 2022. Specifically, according to the survey results announced by Anphabe, the brand awareness of Imexpharm in the pharmaceutical industry was 81.5 per cent, higher than the industry average of 76.7 per cent.

Trần Thị Đào, General Director of Imexpharm, said: "This award is a positive recognition for Imexpharm's relentless efforts over nearly half a century in creating a friendly, transparent, fair, and rewarding work environment."

She added that Imexpharm always prioritises training activities, team cohesion, and taking care of employees' well-being, helping them feel secure in their work and fostering strong bonds with the company to build a team of competent, physically fit, and mentally resilient employees.

Established in 1977 in Đồng Tháp Province, Imexpharm has to date owned four manufacturing clusters, including three EU-GMP manufacturing clusters with 11 production lines that meet EU-GMP standards.

Currently, Imexpharm is a manufacturing partner for many leading multinational pharmaceutical corporations such as Sandoz, Robison Pharma, DP Pharma, Galien, Pharmacience Canada, and Sanofi-Aventis. As of the end of 2022, Imexpharm had obtained 12 registrations for seven products in Europe. — VNS

(Vietnam News)